Lower risk of serious adverse events and no increased risk of cancer after PBSC versus bone marrow donation
Cette étude met en évidence, par rapport à la population générale, une absence d'augmentation du risque de cancer chez les donneurs de moelle osseuse (2 727 cas) et les donneurs de cellules souches du sang périphérique (6 768 cas)
We compared serious early and late events experienced by 2726 BM and 6768 PBSC donors who underwent collection of peripheral blood stem cells (PBSC) or bone marrow (BM) between 2004 and 2009 as part of a prospective study through the National Marrow Donor Program. Standardized FDA definitions for serious adverse events (SAEs) were used and all events were reviewed by an independent physician panel. BM donors had an increased risk of SAEs (2.38% BM vs. 0.56% PBSC; OR 4.13, p < 0.001), and women were twice as likely to experience an SAE (OR for men 0.50, p=0.005). Restricting the analysis to life-threatening, unexpected, or chronic/disabling events, BM donors maintained an increased risk for SAEs (0.99% BM vs. 0.31% PBSC; OR 3.20, p < 0.001). Notably, the incidence of cancer, autoimmune illness, and thrombosis after donation was similar in BM versus PBSC donors. In addition, cancer incidence in PBSC donors was less than that reported in the general population (SEER database). In conclusion, SAEs after donation are rare, but more often occurred in BM donors and women. In addition, there was no evidence of increased risk of cancer, autoimmune illness, and stroke in donors receiving G-CSF during this period of observation.
Blood 2014